antiproteinuric and antiinflammatory effect of vitamin D comparing with direct renin inhibitor in DKD

Antiproteinuric and Anti-Inflammatory effect of Vitamin D comparing with Direct renin inhibitor in Diabetic Kidney Disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20120000008

Enrollment

Registered

2012-06-27

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age > 18 DKD with eGFR > 15 ml/min Optimal dose of ACEI or ARB &#8805

Interventions

Aliskiren 150 mg OD x 6 wks,Calcitriol 0.5 microgram twice a week

Experimental Drug,Experimental Drug

Aliskiren,Calcitriol

Eligibility

Sex/Gender

All

Age

19 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age > 18 DKD with eGFR > 15 ml/min Optimal dose of ACEI or ARB ≥ 3 months Stable BP control ( ΔSBP ≤ 10% ) Stable renal function ( ΔeGFR ≤ 10% ) Stable glycemic control ( ΔHbA1C ≤ 15% x 2 in past 3 months )

Exclusion criteria

Exclusion criteria: Poorly controlled HT ( BP ≥ 150/95 mmHg ) Poorly controlled DM ( HbA1C > 8.5 % ) Hyperkalemia > 5 mg/dl Hyperphosphatemia > 6 mg/dl Hypercalcemia > 10 mg/dl Taking vitamin D or its analog

Design outcomes

Primary

Measure	Time frame
proteinuria and inflammatory marker reduction 0, 6 wk pair t-test	—

Secondary

Measure	Time frame
change in pro-BNP and PTH 0,6 wk pair t-test	—

Countries

Thailand

Contacts

Public ContactSathit Kurathong

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026